



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 3rd, 2023

1:05 PM - 4:45 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Caryn Mickelson, PharmD; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Kendal Pucik, OSU COP P4; Brandon Wells; Trevor Douglass, DC, MPH; Amanda Parish, LCSW; Jennifer Bowen; Dee Weston, JD; John McIlveen, PhD, LMHC

Audience: Eleasa Sokolski, MD OHSU*; Eowyn Rieke, MD Fora Health*; Joey Razzano, NW Rett Syndrome Association; Benjamin Skoog, Acadia Pharm; Tiffany Dickey, Aimmune; Rochelle Yang, Teva*; Erin Nowak, AbbVie; Jennifer Davis, Gilead; Melissa Abbott, Eisai; Gary Parenteau, Dexcom; Matt Worthy, OHSU; Tiina Andrews, UHA; Brandie Feger, Advanced Health CCO; Mark Kantor, AllCare CCO; Saghi Maleki; Takeda Pharm; Lori McDermott, Viking HCS; Deron Grothe, Braeburn; Michael Foster, BMS; Rob Booth, AbbVie; Chris Johnson, Biomarin; Sean Staff, Acadia; Melissa Bailey, Hall; Georgette Dzwilewski, Indivior; Nirmal Ghuman, Janssen; Mike Donabedian, Sarepta; Michele Sabados, Alkermes; Jim Slater, CareOregon; Ann Nelson, Vertex; Manheet Malhi, UHA Student; Christine Donahue, CSL Behring; Renetta Mosley, Acadia; Mark Borkovec, ALK-Abello; Alison Bass, CSL Behring; Shauna Wick, Trillium; David Shirkey, ALK-Abello; Shannon Lee, Trillium; Pam Storey; Matt Metcalf, CSL Vifor; Norm Navarro, Providence; Jeff White, Sumitomo; Jennifer Davis, Gilead; Rick Kegler; Bryan Mauk, Vertex; Charlie Flynn; Seth Fritts; Lisa Pulver; Scott Brown; Mike Mattoon, Acadia; Neil Bair, Acadia; June Sanson; Bill Robie, NHF; Jason Kniffin

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and June 2023 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor
- D. Department Update provided by Andrew Gibler, PharmD
- E. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

- A. Quarterly Utilization Report
- B. Oncology Prior Authorization (PA) Updates
Recommendation:
 - Add: Epkinly™ (epcoritamab-bysp); and Columvi™ (glofitamab-gxbm) to Table 1 in the Oncology Agents prior authorization (PA) criteria
- C. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
Recommendation:
 - Evaluate costs in executive session**ACTION: Motion to approve, 2nd, all in favor**

III. DUR ACTIVITIES

- A. ProDUR Report: Lan Starkweather, PharmD
- B. RetroDUR Report: Dave Engen, PharmD
- C. Oregon State Drug Review: Kathy Sentena, PharmD
 - 1. Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescriptions
 - 2. COVID-19 Therapeutics Update: Where Are We Now?

IV. DUR NEW BUSINESS

- A. Sublingual Buprenorphine Quantity Limit Policy Evaluation: Sarah Servid, PharmD
Recommendations:
 - Increase dose limit to 32 mg daily for sublingual buprenorphine formulations
 - Update current PA criteria to permit use of higher doses for OUD with medical justification

- Implement a days' supply limit for all sublingual buprenorphine formulations to support quantity limits

ACTION: Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Daybue™ (trofinetide) New Drug Evaluation: Deanna Moretz, PharmD

Recommendations:

- Maintain trofinetide as non-preferred on the PDL
- Implement proposed PA criteria for trofinetide to ensure medically appropriate use

ACTION: The Committee amended the proposed PA criteria to remove assessment for type of Rett syndrome and to refer requests to the medical director when Rett syndrome has not been genetically confirmed

Motion to approve, 2nd, all in favor

B. Benign Prostatic Hyperplasia (BPH) Class Update: Kathy Sentena, PharmD

Recommendations:

- No PDL changes recommended based on review of recently published evidence
- Update PA criteria as proposed and remove the renewal criteria
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. Vowst™ (oral fecal microbiota spores, live-brpk) NDE: Deanna Moretz, PharmD

Recommendations:

- Maintain oral fecal microbiota capsules as non-preferred on the PDL subject to PA
- Add oral fecal microbiota capsules to the "Prevention of C. difficile Recurrence" clinical PA criteria

ACTION: The Committee amended the proposed PA criteria to add step therapy that requires fecal microbiota transplant before use of bezlotoxumab

Motion to approve, 2nd, all in favor

D. Non-injectable Allergen Immunotherapy Class Review: Deanna Moretz, PharmD

Recommendations:

- Add Grastek®, Oralair®, Ragwitek®, and Odactra® sublingual tablets to the "Immunotherapy Desensitization, Non-Injectable" PDL class as non-preferred
- Implement the proposed "Sublingual Immunotherapy Tablets" PA criteria to allow for coverage under the EPSDT program and for allergic rhinitis complicated by a comorbidity such as asthma
- Evaluate costs in executive session

ACTION: The Committee amended the proposed PA criteria to only permit the use of Odactra® (dust mite sublingual immunotherapy) in people with allergic rhinitis complicated by comorbid asthma

Motion to approve, 2nd, all in favor

E. Gene Therapies for Beta-thalassemia and Hemophilia B DERP Summary

Topic Deferred

F. Endocrine Therapies Class & Prior Authorization Updates

GnRH Agonists Class Update/PA Criteria: Deanna Moretz, PharmD

Estrogens & Testosterone PA Criteria: Sarah Servid, PharmD

Recommendations:

- No PDL changes recommended based on review of recently published evidence
- The Committee supported revising the GnRH agonists, estrogen, and testosterone PA criteria to comport with recently enacted state legislation, HB 2002, as well as to include an EPSDT assessment.
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Caryn Mickelson, PharmD; Eriko Onishi, MD; Bill Origer, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. CGRP Inhibitors

Make Ubrelyv™ (ubrogepant) preferred on the PDL contingent on acceptance of a supplemental rebate offer that is similar in population scope to current contract

ACTION: Motion to approve, 2nd, all in favor

B. Benign Prostatic Hyperplasia (BPH) Class

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

C. Clostridioides difficile Drug Class

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

D. Allergen Immunotherapy

Make all sublingual tablets non-preferred

ACTION: Motion to approve, 2nd, all in favor

E. Endocrine Therapies Class

Make Lupron Depot-Ped kit formulations (1 month, 3 month, and 6 month) preferred

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN